Business Context and Reporting Period
This Form 8-K reports on events occurring on June 11, 2026, specifically the 2026 Annual Meeting of Stockholders for CareDx, Inc. (CDNA). The filing details the outcomes of five proposals voted on by stockholders, including director elections, auditor ratification, executive compensation advisory votes, and an amendment to the company's equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Stockholders representing approximately 93% of total outstanding shares (48,142,732 shares) participated in the meeting. The following material actions were approved:
- Director Elections: Five directors were elected to serve one-year terms expiring at the 2027 Annual Meeting: Fred E. Cohen, R. Bryan Riggsbee, and Suresh Gunasekaran (Class II); Michael D. Goldberg and John W. Hanna (Class III).
- Equity Plan Amendment: Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the available shares reserved by 1,600,000 shares (approximately 3.1% of common shares issued and outstanding).
- Auditor Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: Stockholders approved the compensation of named executive officers on a non-binding advisory basis.
- Compensation Vote Frequency: Stockholders advised in favor of holding advisory votes on executive compensation every one year.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors. The primary focus is the administrative approval of the equity plan amendment and the ratification of corporate governance matters.
Key Facts for Investor Verification
- Verify the impact of the 1,600,000 share increase to the 2024 Equity Incentive Plan on potential future dilution.
- Confirm the terms of the newly elected directors' one-year terms and their alignment with the company's strategic goals.
- Note that the advisory vote on executive compensation frequency was set to annual, indicating a preference for frequent oversight.
- Review the full text of Exhibit 10.1 (Amendment No. 2 to the 2024 Equity Incentive Plan) for specific terms regarding the share increase.